{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"630","upperLimit":"1570","value":"851.5"},{"groupId":"OG001","lowerLimit":"531","upperLimit":"1834","value":"715"}]}],"title":"Total T cells CD3+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"388","upperLimit":"1094","value":"591"},{"groupId":"OG001","lowerLimit":"316","upperLimit":"1055","value":"525"}]}],"title":"Helper T cells CD3+/CD4+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"528","value":"296"},{"groupId":"OG001","lowerLimit":"117","upperLimit":"1243","value":"183"}]}],"title":"Cytotoxic T cells CD3+/CD8+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98","upperLimit":"662","value":"249.5"},{"groupId":"OG001","lowerLimit":"180","upperLimit":"418","value":"228"}]}],"title":"Natural Killer cells CD56+/CD16+"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Phenotypic changes in peripheral blood cells following CC-5013 (lenalidomide) administration especially in regards to CD3, CD4, CD8 T cells, and NK and NKT cells.","dispersionType":"Full Range","groups":[{"description":"Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.","id":"OG000","title":"Lenalidomide"},{"description":"Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Phenotypic Changes","type":"SECONDARY","unitOfMeasure":"cells/cmm"}